{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "11737386",
  "DateCompleted": {
    "Year": "2002",
    "Month": "04",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "11",
    "Day": "05"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1464-2662",
      "JournalIssue": {
        "Volume": "2",
        "Issue": "2",
        "PubDate": {
          "Year": "2001",
          "Month": "Apr"
        }
      },
      "Title": "HIV medicine",
      "ISOAbbreviation": "HIV Med"
    },
    "ArticleTitle": "Antiretroviral treatment of central nervous system HIV-1 infection: a review.",
    "Pagination": {
      "StartPage": "97",
      "EndPage": "104",
      "MedlinePgn": "97-104"
    },
    "Abstract": {
      "AbstractText": [
        "HIV-1 infects the central nervous system (CNS) and it has been feared that the CNS may be a sanctuary site where HIV-1 could hide and continue to replicate despite otherwise effective antiretroviral treatment. Neurological HIV-1 related symptoms, cerebrospinal fluid (CSF) viral load, intrathecal immunoactivation and CSF drug concentration measurements are considered in this review of antiretroviral treatment effects on CNS HIV-1 infection. We conclude that antiretroviral combination treatment regimens improve neurocognitive symptoms in HIV-1 infection and substantially lower CSF viral load. The threat of an increasing number of patients with neurological symptoms and continued HIV-1 replication in the brain despite otherwise effective antiretroviral therapy has not yet proved to be a problem. It is, however, important to keep this potential risk in mind, and more longitudinal prospective studies addressing the issue of antiretroviral treatment effects on CNS HIV-1 infection are needed."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, Sahlgrenska University Hospital, G\u00f6teborg, Sweden. magnus.gisslen@infect.gu.se"
          }
        ],
        "LastName": "Gissl\u00e9n",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hagberg",
        "ForeName": "L",
        "Initials": "L"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "HIV Med",
    "NlmUniqueID": "100897392",
    "ISSNLinking": "1464-2662"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-HIV Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "cerebrospinal fluid",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-HIV Agents"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "Central Nervous System"
    },
    {
      "QualifierName": [
        "cerebrospinal fluid",
        "drug therapy",
        "virology"
      ],
      "DescriptorName": "Central Nervous System Infections"
    },
    {
      "QualifierName": [
        "cerebrospinal fluid",
        "drug therapy"
      ],
      "DescriptorName": "HIV Infections"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "HIV-1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Viral Load"
    }
  ],
  "NumberOfReferences": "65"
}